ERBB2 and breast cancer: Currently, T-DM1 is approved for the metastatic HER2-positive BC patients at the second line after receiving trastuzumab and taxanes, and for the HER2-positive early BC patients at the adjuvant setting who have residual invasive disease after neoadjuvant treatment with a taxane and trastuzumab-based regimen [6].